Ikena

Ikena Oncology is a clinical-stage biotechnology company focused on developing precision medicines for cancer by targeting key signaling pathways like Hippo and RAS. The company's pipeline has historically included IK-930, a TEAD inhibitor, and IK-595, a MEK-RAF complex inhibitor, both aimed at treating genetically defined solid tumors. In May 2024, Ikena announced a significant strategic shift, discontinuing its primary clinical programs and reducing its workforce by over 50% to preserve capital. The company is currently exploring strategic alternatives, such as a merger, sale, or other business combinations, to maximize shareholder value. Headquartered in Boston, Ikena was founded in 2016 and is listed on the NASDAQ exchange.